Mary C. Tanner
Director/Board Member chez PEARL HOLDINGS ACQUISITION CORP
Profil
Mary C.
Tanner is the founder of Evolution Life Science Partners.
She is currently an Independent Director at Pearl Holdings Acquisition Corp.
Her former positions include Senior Managing Director at Bear, Stearns & Co., Inc., Senior Managing Director at Lehman Brothers, Inc., Managing Director at Peter J.
Solomon Co. LP, and Member-Supervisory Board at Evotec SE.
She has also served as a Director at Block Drug Co., Inc., ARIAD Pharmaceuticals, Inc., HaptoGuard, Inc., Calliditas Therapeutics Suisse SA, and Genticel SA, and as a Non-Executive Director at Lineagen, Inc. and Pangenx, Inc. Additionally, she was a Member-Deans Board at Yale School of Medicine.
Ms. Tanner received her undergraduate degree from Harvard University in 1973.
Postes actifs de Mary C. Tanner
| Sociétés | Poste | Début |
|---|---|---|
| PEARL HOLDINGS ACQUISITION CORP | Director/Board Member | 01/12/2021 |
Evolution Life Science Partners
 Evolution Life Science Partners Investment ManagersFinance Evolution Life Science Partners is a life science investment bank that specializes in licensing, strategic advisory, M&A, and capital raising. The private company is based in San Francisco, CA. The CEOs are Anton G. Gueth, David C. Parke. The company was founded by Mary C. Tanner. | Founder | - |
Anciens postes connus de Mary C. Tanner
| Sociétés | Poste | Fin |
|---|---|---|
| GENKYOTEX SA. | Director/Board Member | 03/11/2020 |
| EVOTEC SE | Director/Board Member | 17/06/2014 |
| Block Drug Co., Inc. | Director/Board Member | 19/03/2013 |
Peter J. Solomon Co. LP
 Peter J. Solomon Co. LP Investment ManagersFinance Peter J. Solomon Co. provides investment advisory services. The company offers corporate finance, restructuring, private financings, merger and acquisitions services. It also offers services to the retail, wholesale, catalogue distribution, consumer products, healthcare and media industries. Peter J. Solomon Co. was founded in 1989 and is headquartered in New York City, NY | Corporate Officer/Principal | - |
| SYNVISTA THERAPEUTICS, INC. | Director/Board Member | 01/01/2009 |
Formation de Mary C. Tanner
| Harvard University | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 3 |
|---|---|
| SYNVISTA THERAPEUTICS, INC. | Health Technology |
| EVOTEC SE | Health Technology |
| PEARL HOLDINGS ACQUISITION CORP | Finance |
| Entreprise privées | 12 |
|---|---|
Bear, Stearns & Co., Inc.
 Bear, Stearns & Co., Inc. Investment Banks/BrokersFinance Bear, Stearns & Co., Inc. is a global investment banking, securities trading and brokerage firm located in New York City with additional offices in Dallas, Boston and San Francisco. The firm is a subsidiary Bear Sterns Cos., Inc. (NYSE: BSC). Their equity research team consists of senior analysts located throughout the world. In addition to domestic coverage, they have research teams focusing on Latin America, Asia and Europe. The analysts use a bottom-up approach to stock selection. The Bear Stearns fixed-income research department provides coverage of every sector of the fixed-income universe. The financial analytics and structured transactions group (F.A.S.T) provides investment research, fixed-income portfolio management and analytical systems, trading technology and general financial expertise. The group also provides a broad range of services to financial institutions including asset-liability management, balance sheet restructuring, receivables-based financing analysis, security and portfolio analysis, peer analysis, and historical and real-time market-based information. | Finance |
| Block Drug Co., Inc. | Health Technology |
Lehman Brothers, Inc.
 Lehman Brothers, Inc. Investment Banks/BrokersFinance A subsidiary of Lehman Brothers Holdings, Inc., Lehman Brothers, Inc. is a broker/dealer headquartered in New York City. They provide global equity and fixed research. The equity research department covers more than 100 sectors. They use a fundamental, quantitative, strategic and tactical research approach. In addition to these Lehman has also developed special products, such as 10 uncommon values and 10 uncommon eurovalues. | Finance |
ARIAD Pharmaceuticals, Inc.
 ARIAD Pharmaceuticals, Inc. BiotechnologyHealth Technology ARIAD Pharmaceuticals, Inc. operates as an oncology company, which engages in the discovery, development, and commercialization of small-molecule drugs for the treatment of cancer. The company was founded by Harvey J. Berger and James E. Rothman on January 8, 1992 and is headquartered in Cambridge, MA. | Health Technology |
HaptoGuard, Inc.
 HaptoGuard, Inc. BiotechnologyHealth Technology HaptoGuard, Inc. develops and commercializes therapeutics for inflammatory diseases. Its products include orally bioavailability and organ selenium mimics of glutathione peroxides that metabolize lipid peroxides. It develops products to research, diagnose, treat, and prevent diseases associated with damage from free radical and reactive oxygen species and diseases of oxidative stress. The company is headquartered in Fort Lee, NJ. | Health Technology |
LineaGen, Inc.
 LineaGen, Inc. Medical/Nursing ServicesHealth Services Lineagen, Inc. provides diagnostic evaluation services. It focuses on genetic disorders such as autism, multiple sclerosis, and chronic obstructive pulmonary diseases. The firm provides FirstStep, which provides physicians with integrated genetic testing, counseling, and developmental screening services. The company was founded by Stephen M. Prescott, Andy Peiffer, Michael S. Paul, Mark F. Leppert, Al R. Harris and Alex S. Lindell in 2006 and is headquartered in Salt Lake City, UT. | Health Services |
Calliditas Therapeutics Suisse SA
 Calliditas Therapeutics Suisse SA Pharmaceuticals: GenericHealth Technology Calliditas Therapeutics Suisse SA engages in the development of NOX therapies. Its platform enables the identification of orally available small-molecules that selectively inhibit specific NOX enzymes, which amplify multiple disease processes such as fibrosis, inflammation, pain processing, cancer development, and neurodegeneration. The company was founded Chihiro Yabe, Robert A. Clark, David Lambeth, and Karl-Heinz Krause in 2006 and is headquartered in Geneva, Switzerland. | Health Technology |
Pangenx, Inc.
 Pangenx, Inc. Pharmaceuticals: MajorHealth Technology Pangenx, Inc. develops medicines. The private company is based in Newton, MA. | Health Technology |
Peter J. Solomon Co. LP
Peter J. Solomon Co. LP Investment ManagersFinance Peter J. Solomon Co. provides investment advisory services. The company offers corporate finance, restructuring, private financings, merger and acquisitions services. It also offers services to the retail, wholesale, catalogue distribution, consumer products, healthcare and media industries. Peter J. Solomon Co. was founded in 1989 and is headquartered in New York City, NY | Finance |
Genticel SA
 Genticel SA BiotechnologyHealth Technology Genticel SA operates as a clinical stage biotechnology company, which focuses on the development of immunotherapies designed to fight infectious diseases and cancer. The company was founded by Bénédikt Timmerman and Ludovic de Meeus d'Argenteuil on October 15, 2001 and is headquartered in Labège, France. | Health Technology |
Evolution Life Science Partners
Evolution Life Science Partners Investment ManagersFinance Evolution Life Science Partners is a life science investment bank that specializes in licensing, strategic advisory, M&A, and capital raising. The private company is based in San Francisco, CA. The CEOs are Anton G. Gueth, David C. Parke. The company was founded by Mary C. Tanner. | Finance |
Calliditas Therapeutics France SAS
 Calliditas Therapeutics France SAS Pharmaceuticals: MajorHealth Technology Calliditas Therapeutics France SAS is a biopharmaceutical company, which engages in the NOX therapies. Its therapeutic approach is based on a selective inhibition of NOX enzymes that amplify multiple disease processes, such as fibrosis, inflammation, pain processing, cancer development, and eurodegeneration. The firm’s platform enables the identification of orally available small molecules that selectively inhibit specific NOX enzymes. The company was founded in 2006 and is headquartered in Saint-Julien-en-Genevois, France. | Health Technology |
